FY2026 EPS Estimate for Moderna Boosted by Analyst

Moderna, Inc. (NASDAQ:MRNA) – Investment analysts at Brookline Capital Markets increased their FY2026 earnings estimates for shares of Moderna in a research report issued to clients and investors on Friday, November 6th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings of ($5.45) per share for the year, up from their previous estimate of ($6.46). Brookline Capital Markets currently has a “Buy” rating on the stock. The consensus estimate for Moderna’s current full-year earnings is ($5.69) per share. Brookline Capital Markets also issued estimates for Moderna’s Q4 2026 earnings at ($2.87) EPS, FY2027 earnings at ($2.79) EPS and FY2028 earnings at ($0.16) EPS.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The firm had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $890.25 million. During the same period last year, the business earned ($0.51) earnings per share. Moderna’s revenue was up 29.2% compared to the same quarter last year.

A number of other analysts also recently issued reports on MRNA. Citigroup restated a “sell” rating on shares of Moderna in a report on Friday, October 23rd. Berenberg Bank increased their price objective on Moderna from $45.00 to $100.00 and gave the stock a “hold” rating in a research report on Friday, September 11th. Bank of America raised their target price on Moderna from $170.00 to $200.00 and gave the stock a “neutral” rating in a research note on Friday, October 9th. Argus upgraded Moderna from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a research report on Friday, August 28th. Finally, UBS Group restated a “neutral” rating on shares of Moderna in a research report on Tuesday, September 22nd. Six investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $113.75.

Moderna Stock Performance

NASDAQ:MRNA opened at $250.83 on Wednesday. The company’s 50-day moving average is $196.68 and its two-hundred day moving average is $93.60. Moderna has a 1-year low of $22.28 and a 1-year high of $280.80. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47. The firm has a market capitalization of $101.49 billion, a price-to-earnings ratio of -35.33 and a beta of 1.16.

Insider Activity

In related news, President Stephen Hoge sold 39,145 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the completion of the transaction, the president owned 1,636,565 shares of the company’s stock, valued at approximately $361,222,626.80. This trade represents a 2.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the sale, the insider owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This trade represents a 4.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 197,251 shares of company stock valued at $33,875,904. Company insiders own 10.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of MRNA. Westpac Banking Corp acquired a new position in Moderna in the 3rd quarter valued at about $1,778,000. Private Advisor Group LLC lifted its position in shares of Moderna by 37.8% during the third quarter. Private Advisor Group LLC now owns 8,807 shares of the company’s stock worth $1,696,000 after purchasing an additional 2,415 shares in the last quarter. Ieq Capital LLC boosted its stake in shares of Moderna by 47.9% in the third quarter. Ieq Capital LLC now owns 13,978 shares of the company’s stock valued at $2,692,000 after purchasing an additional 4,530 shares during the period. Checchi Capital Advisers LLC purchased a new position in shares of Moderna in the third quarter valued at approximately $312,000. Finally, Banco BTG Pactual S.A. acquired a new position in shares of Moderna in the third quarter valued at approximately $458,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported third-quarter revenue of about $1.3 billion, up 29% year over year and ahead of expectations, and raised its 2026 revenue-growth outlook to 15%–25%. Lower costs and respiratory-vaccine gains also supported the improved outlook. Why is Moderna stock soaring today?
• Positive Sentiment: Investors also have a potential longer-term catalyst in personalized cancer vaccine intismeran. Phase 3 results reportedly showed a 42% reduction in melanoma recurrence or death, and Moderna is targeting an FDA filing by year-end 2026, which could lead to a decision in 2027. Can Moderna’s first cancer therapy win FDA approval in 2027?
• Neutral Sentiment: Moderna is scheduled to present at the Jefferies Global Health Care Conference on November 18. The event could provide updates, but the announcement itself does not change the company’s outlook. Moderna to present at upcoming conference
• Negative Sentiment: Despite the earnings beat, nearly all of Moderna’s revenue still comes from COVID-related products, leaving investors focused on the challenge of building durable sales beyond the pandemic market. That concern may weigh more heavily after the stock’s sharp recent run. Moderna’s Q3 numbers may not be enough to make the stock a buy
• Negative Sentiment: Valuation is another headwind: Goldman Sachs raised its price target but kept a neutral rating, while a separate analysis put fair value well below the prevailing share price. Brookline also made modest reductions to its long-term earnings estimates, despite maintaining a Buy rating.

Moderna Company Profile

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.